SLC6A3 and Parkinson disease: To meet this need, the Critical Path for Parkinson’s (CPP) used an integrated patient-level database consisting of data from 672 patients from 2 independent clinical studies to build models that describe the use of dopamine transporter (DAT) neuroimaging as an enrichment biomarker for early stages of PD.